Clinical Edge Journal Scan

Regular vitamin E supplementation may help alleviate joint discomfort in RA


 

Key clinical point : Regular vitamin E supplementation in patients with rheumatoid arthritis (RA) may help reduce joint discomfort, edema, and stiffness, thus enhancing the overall quality of life.

Major finding: Patients with RA who received regular vitamin E supplementation showed improvements in uncomfortable joints (mean difference [MD] −0.62; 95% CI −12.59 to 11.36) and tender joints (MD −1.66; 95% CI −6.32 to 2.99) compared with those who received placebo, fish oil, or other medications, without any significant safety concerns.

Study details: This was a systematic review and meta-analysis of nine studies including 39,845 individuals with RA who received vitamin E (experimental group) or placebo, fish oil, or other medications (control group).

Disclosures: This study was supported by funding from the Natural Science Foundation of Shaanxi Province, China. The authors declared no competing interests.

Source: Kou H et al. Effect of vitamin E supplementation in rheumatoid arthritis: A systematic review and meta-analysis. Eur J Clin Nutr. 2022 (Apr 25). Doi: 10.1038/s41430-022-01148-9

Recommended Reading

Parents’ autoimmune diseases may affect children’s development
MDedge Rheumatology
Upadacitinib earns FDA approval for ankylosing spondylitis 
MDedge Rheumatology
Reduced-frequency methotrexate monitoring causes no harm
MDedge Rheumatology
‘Goodie bag’ pill mill doctor sentenced to 2 decades in prison
MDedge Rheumatology
‘Shielding’ status provides best indicator of COVID-19 mortality in U.K. arthritis population
MDedge Rheumatology
RA: Upadacitinib plus elsubrutinib combo (ABBV-599) shows promise in phase 2
MDedge Rheumatology
Higher COVID-19 hospitalization risk in RA vs. general population despite vaccination
MDedge Rheumatology
Prognostic factors for mortality in rheumatoid arthritis-associated interstitial lung disease
MDedge Rheumatology
Poor prognostic joint locations in early RA may indicate rapidly progressing disease
MDedge Rheumatology
Risk of developing dementia is similar with tofacitinib, tocilizumab, or TNFi vs. abatacept in RA
MDedge Rheumatology